SFS
KPTI icon

Sowell Financial Services’s Karyopharm Therapeutics KPTI Stock Holding History

Sowell Financial Services’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-84
Closed -$10K – 1710
2021
Q1 		$10K Buy
84
+7
+9% +$1.48K ﹤0.01% 2313
2020
Q4 		$18K Buy
77
+69
+863% +$16K ﹤0.01% 1779
2020
Q3 		$2K Sell
8
-15
-65% -$3.67K ﹤0.01% 2231
2020
Q2 		$6K Sell
23
-88
-79% -$26K ﹤0.01% 1843
2020
Q1 		$32K Sell
111
-135
-55% -$37.2K ﹤0.01% 1214
2019
Q4 		$71K Buy
+246
New +$53.4K 0.01% 1015

Other funds holding KPTI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
DMPV
Delphi Management Partners VIII San Mateo, California $138M AUM 56.74% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Sowell Financial Services's KPTI Position: Q2 2021 in Review

Sowell Financial Services sold out of Karyopharm Therapeutics (KPTI) in Q2 2021, closing a stake of 84 shares — an estimated $10K sold.

Sowell Financial Services first reported a position in KPTI in Q4 2019 and held it in 6 quarters. The position peaked at $71K in Q4 2019. 153 funds tracked by Wall St. Rank hold KPTI as of Q2 2021.

  • Sowell Financial Services reported no remaining Karyopharm Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Sowell Financial Services sold 84 Karyopharm Therapeutics shares in Q2 2021, an estimated $10K.
  • Sowell Financial Services first reported a position in Karyopharm Therapeutics in Q4 2019 and held it in 6 quarters.
  • Sowell Financial Services's Karyopharm Therapeutics position peaked at $71K in Q4 2019.
  • 153 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2021.

Based on Sowell Financial Services's 13F filing for Q2 2021, filed 5 Aug 2021.